KEN ZREBIEC
SVP Manufacturing Operations, Veranova

Abstract

As the pharmaceutical industry undergoes transformations driven by innovation, outsourcing plays a vital role in drug development. Contract development and manufacturing organizations (CDMOs) are no longer simply production capacity providers but have become integral collaborative partners. Choosing the right CDMO is crucial amid global trends and events. At Veranova, we work closely with our partners to manage industry demands with confidence. In this article, Ken Zrebiec, Veranova’s Senior VP of Manufacturing Operations, explores how pharma companies leverage specialized CDMO expertise to enhance development capabilities.

Introduction
In recent decades, the pharmaceutical industry has undergone significant changes. Driven by innovation and growth in specialized areas, more pharmaceutical companies are choosing to partner with CDMOs to obtain a competitive edge. As a result, CDMOs have become technology and innovation leaders across key stages of drug discovery, development, and manufacturing.

However, as global trends and events, such as supply chain disruptions and geopolitical tensions, continue to impact the industry, it will be important to reassess outsourcing strategies against new benchmarks. As pharmaceutical development and manufacturing evolves, the nature of partnerships between CDMOs and drug manufacturers will continue to change to navigate the demands of the development pipeline. In order to gain an edge in the changing landscape, a company must choose the correct CDMO partner for its needs.

Understanding the need and drive for outsourcing
Traditionally, outsourcing to development and manufacturing partners has provided a tool for drug manufacturers to increase production capacity. However, ...